144 related articles for article (PubMed ID: 25036984)
21. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
[TBL] [Abstract][Full Text] [Related]
22. Activated Jak2 with the V617F point mutation promotes G1/S phase transition.
Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; Podar K; Griffin JD; Sattler M
J Biol Chem; 2006 Jun; 281(26):18177-83. PubMed ID: 16632470
[TBL] [Abstract][Full Text] [Related]
23. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
Kirabo A; Embury J; Kiss R; Polgár T; Gali M; Majumder A; Bisht KS; Cogle CR; Keseru GM; Sayeski PP
J Biol Chem; 2011 Feb; 286(6):4280-91. PubMed ID: 21127060
[TBL] [Abstract][Full Text] [Related]
24. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
25. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Leukemia; 2014 Aug; 28(8):1627-35. PubMed ID: 24480985
[TBL] [Abstract][Full Text] [Related]
26. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K; Kameda T; Markovtsov V; Shimoda HK; Tonkin E; Fang S; Liu C; Gelman M; Lang W; Romero J; McLaughlin J; Bhamidipati S; Clough J; Low C; Reitsma A; Siu S; Pine P; Park G; Torneros A; Duan M; Singh R; Payan DG; Matsunaga T; Hitoshi Y; Shimoda K
Blood; 2011 Jun; 117(25):6866-75. PubMed ID: 21531978
[TBL] [Abstract][Full Text] [Related]
27. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
[TBL] [Abstract][Full Text] [Related]
28. Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect.
Vecchiarelli-Federico LM; Liu T; Yao Y; Gao Y; Li Y; Li YJ; Ben-David Y
Int J Oncol; 2017 Aug; 51(2):456-466. PubMed ID: 28586009
[TBL] [Abstract][Full Text] [Related]
29. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
[TBL] [Abstract][Full Text] [Related]
30. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Haematologica; 2012 Sep; 97(9):1389-93. PubMed ID: 22371173
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
32. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.
Xing S; Wanting TH; Zhao W; Ma J; Wang S; Xu X; Li Q; Fu X; Xu M; Zhao ZJ
Blood; 2008 May; 111(10):5109-17. PubMed ID: 18334677
[TBL] [Abstract][Full Text] [Related]
33. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
Prick J; de Haan G; Green AR; Kent DG
Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
[TBL] [Abstract][Full Text] [Related]
34. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of
Yamaji T; Shide K; Kameda T; Sekine M; Kamiunten A; Hidaka T; Kubuki Y; Shimoda H; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Shimoda K
Anticancer Res; 2017 Jul; 37(7):3841-3847. PubMed ID: 28668884
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
36. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
38. Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.
Shi K; Zhao W; Chen Y; Ho WT; Yang P; Zhao ZJ
J Hematol Oncol; 2014 Mar; 7():25. PubMed ID: 24646493
[TBL] [Abstract][Full Text] [Related]
39. JAK2 inhibition in JAK2
Dahlström J; Xia C; Xing X; Yuan X; Björkholm M; Xu D
Biochem Biophys Res Commun; 2020 Jun; 527(2):425-431. PubMed ID: 32334833
[TBL] [Abstract][Full Text] [Related]
40. Critical requirement for Stat5 in a mouse model of polycythemia vera.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]